Vasculitis & polymyalgia rheumatica
Tumor necrosis factor alpha inhibitors in Behçet’s disease: indications, efficacy, and safety of two widely used agents
Authors' conclusion
Both IFX and ADA were highly effective and well tolerated in severe or refractory BD. ADA provided durable control in mucocutaneous and ocular phenotypes, whereas IFX offered rapid remission in vascular and neurological disease.
Study context
- Population
- Behçet's disease (BD) patients receiving first anti-TNF therapy, April 2020–2025, single centre
- Participants
- 87 patients
- Exposure
- Infliximab vs adalimumab as first anti-TNF therapy
- Infliximab (IFX)n = 45
- And adalimumab (ADA)n = 42
- Outcome
- Complete remission (initial)
Methodological detailssingle-centre, real-world
- Single-centre
- Real-world
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Complete remission at last visit
Relapses
Drug retention
Time to relapse
Relapses
- Relapses occurred more often and earlier with IFX
Drug retention
- Drug retention comparable
Safety
Adverse events
- Adverse event rates comparable, ∼16% adverse events
Severe adverse events
- No severe events occurred
Original publication
Tumor necrosis factor alpha inhibitors in Behçet’s disease: indications, efficacy, and safety of two widely used agents. Rheumatology (Oxford). Published 13 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →